Vanguard Global Advisers
HBIO icon

Vanguard Global Advisers’s Harvard Bioscience HBIO Stock Holding History

Vanguard Global Advisers’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.51K Hold
1,221
– – ﹤0.01% 3518
2026
Q1 		$5.95K Buy
+1,221
New +$6.82K ﹤0.01% 3544

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's HBIO Position: Q2 2026 in Review

Vanguard Global Advisers held its Harvard Bioscience (HBIO) position steady in Q2 2026 at 1,221 shares worth $7.51K. The position accounts for ﹤0.01% of the portfolio, ranked #3518.

Vanguard Global Advisers first reported a position in HBIO in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

  • Vanguard Global Advisers held 1,221 shares of Harvard Bioscience worth $7.51K as of Q2 2026.
  • Vanguard Global Advisers left its Harvard Bioscience share count unchanged in Q2 2026.
  • Harvard Bioscience made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3518 holding.
  • Vanguard Global Advisers first reported a position in Harvard Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.